Literature DB >> 26970681

Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort.

Umut Kalyoncu1, Dilek Solmaz2, Hakan Emmungil3, Ayten Yazici4, Timucin Kasifoglu5, Gezmiş Kimyon6, Ayşe Balkarli7, Cemal Bes8, Mustafa Ozmen9, Fatma Alibaz-Oner10, Sükran Erten11, Yonca Cagatay12, Gözde Yıldırım Cetin13, Sedat Yilmaz14, Fatih Yildiz15, Omer Nuri Pamuk16, Orhan Kucuksahin17, Levent Kilic18, Veli Yazisiz19, Omer Karadag20, Süleyman Serdar Koca21, Mutlu Hayran22, Servet Akar23, Kenan Aksu24, Nurullah Akkoc25, Gokhan Keser26, Emel Gonullu27, Bunyamin Kisacik28, Ahmet Mesut Onat29, Mehmet Soy30, Nevsun Inanc31, Haner Direskeneli32, Mehmet Sayarlioglu33, Eren Erken34, Murat Turgay35, Ayse Cefle36, Ihsan Ertenli37, Salih Pay38.   

Abstract

BACKGROUND: Adult-onset Still's disease (AOSD) is a rare condition, and treatment choices are frequently dependent on expert opinions. The objectives of the present study were to assess treatment modalities, disease course, and the factors influencing the outcome of patients with AOSD.
METHODS: A multicenter study was used to reach sufficient patient numbers. The diagnosis of AOSD was based on the Yamaguchi criteria. The data collected included patient age, gender, age at the time of diagnosis, delay time for the diagnosis, typical AOSD rash, arthralgia, arthritis, myalgia, sore throat, lymphadenopathy, hepatomegaly, splenomegaly, pleuritis, pericarditis, and other rare findings. The laboratory findings of the patients were also recorded. The drugs initiated after the establishment of a diagnosis and the induction of remission with the first treatment was recorded. Disease patterns and related factors were also investigated. A multivariate analysis was performed to assess the factors related to remission.
RESULTS: The initial data of 356 patients (210 females; 59%) from 19 centers were evaluated. The median age at onset was 32 (16-88) years, and the median follow-up time was 22 months (0-180). Fever (95.8%), arthralgia (94.9%), typical AOSD rash (66.9%), arthritis (64.6%), sore throat (63.5%), and myalgia (52.8%) were the most frequent clinical features. It was found that 254 of the 306 patients (83.0%) displayed remission with the initial treatment, including corticosteroids plus methotrexate with or without other disease-modifying antirheumatic drugs. The multivariate analysis revealed that the male sex, delayed diagnosis of more than 6 months, failure to achieve remission with initial treatment, and arthritis involving wrist/elbow joints were related to the chronic disease course.
CONCLUSION: Induction of remission with initial treatment was achieved in the majority of AOSD patients. Failure to achieve remission with initial treatment as well as a delayed diagnosis implicated a chronic disease course in AOSD.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adult-onset Still's disease; Disease modifying anti-rheumatic drugs; Disease pattern; Remission

Mesh:

Substances:

Year:  2016        PMID: 26970681     DOI: 10.1016/j.jaut.2016.02.010

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  22 in total

1.  Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: a longitudinal prospective study.

Authors:  Emre Bilgin; Mutlu Hayran; Abdulsamet Erden; Berkan Armağan; Alper Sarı; Levent Kılıç; Ali Akdoğan; Ömer Karadağ; Şule Apraş Bilgen; Sedat Kiraz; İhsan Ertenli; Umut Kalyoncu
Journal:  Clin Rheumatol       Date:  2019-02-01       Impact factor: 2.980

2.  Identification of prognostic factors and construction of a nomogram for patients with relapse/refractory adult-onset Still's disease.

Authors:  Ruxue Yin; Gangjian Wang; Xiaopei Yang; Lei Zhang; Shuolin Wang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-05-18       Impact factor: 2.980

Review 3.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

Review 4.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 5.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

6.  The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.

Authors:  Kuo-Tung Tang; Chia-Wei Hsieh; Hsin-Hua Chen; Yi-Ming Chen; Shih-Hsin Chang; Po-Hao Huang; Joung-Liang Lan; Der-Yuan Chen
Journal:  Clin Rheumatol       Date:  2021-09-17       Impact factor: 2.980

Review 7.  Progress in Biological Therapies for Adult-Onset Still's Disease.

Authors:  Paola Galozzi; Sara Bindoli; Andrea Doria; Paolo Sfriso
Journal:  Biologics       Date:  2022-04-21

8.  Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers.

Authors:  Piero Ruscitti; Paola Cipriani; Francesco Masedu; Daniela Iacono; Francesco Ciccia; Vasiliki Liakouli; Giuliana Guggino; Francesco Carubbi; Onorina Berardicurti; Paola Di Benedetto; Marco Valenti; Giovanni Triolo; Gabriele Valentini; Roberto Giacomelli
Journal:  BMC Med       Date:  2016-12-01       Impact factor: 8.775

Review 9.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

10.  Impaired autophagic flux and its related inflammation in patients with adult-onset Still's disease.

Authors:  Chia-Wei Hsieh; Chun-Yu Chang; Yi-Ming Chen; Hsin-Hua Chen; Wei-Ting Hung; Ning-Rong Gung; Shiow-Jiuan Wey; Der-Yuan Chen
Journal:  Oncotarget       Date:  2017-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.